Intent to Sole Source - BD Bioscience Reagents

The document outlines a comprehensive procurement plan for various BD Biosciences products, including antibodies, reagents, kits, and laboratory equipment, for a five-year period from 2026 to 2030. The initial projected cost for 2026 is $349,699.04, with an estimated increase of 8% per year for antibodies and a general increase for other categories. The total estimated cost over five years is $1,776,695.83. The procurement includes a wide range of items such as flow cytometry antibodies (CD3, CD4, CD8, CD14, CD19, CD45, CD56, etc.), specialized reagents like BD FACS™ Sheath Fluid and various BD Pharmingen™ and BD Horizon™ products, as well as BD Rhapsody™ kits for single-cell analysis. The plan also details essential consumables and instrument parts for FACSLyric cytometers and LWA systems. The procurement indicates an ongoing need for these supplies to support laboratory operations and research activities.

This Statement of Work outlines a contract for the National Institutes of Health (NIH) Clinical Center's Department of Transfusion Medicine/Center for Cellular Engineering (CCE) to procure reagents and disposables. These supplies are crucial for cell culture, depletion, and enrichment, supporting NIH's intramural clinical trials that treat patients with various diseases, including cancer. The contract, valued at $1,776,695.83, covers a performance period from February 1, 2026, to September 30, 2030, with a 12-month base and three 12-month options. The contractor will supply specific reagents and consumables, primarily from BD Biosciences, for approximately 100 flow cytometry assays annually. Key requirements include providing technical support at no additional cost, ensuring minimum shelf-life for delivered products, and replacing damaged or defective items. The NIH-CC CCE, PACT Section will be responsible for using the products according to instructions and reporting any shipment issues.

The National Institutes of Health (NIH) is seeking to purchase reagents and consumables from BD Biosciences for clinical patient-care quality control flow cytometry assays. This acquisition, estimated at $1,776,695.83, is justified as a sole-source procurement under FAR 6.302-1 due to BD Biosciences being the only manufacturer of the required GMP-level reagents and supplies. The Center of Cellular Engineering (CCE) at NIH uses BD Biosciences' FACSLyris flow cytometer, and switching vendors would require extensive, costly, and risky re-validation, potentially jeopardizing patient care and clinical trials. The contract will be a firm-fixed-price agreement, and the cost is anticipated to be fair and reasonable with government discounts.